LGALS3 and portal hypertension: Galectin-3 (AGE-R3) has also been associated with inflammation and liver fibrosis11 and a Phase 2a multi-centre trial is underway in individuals with portal hypertension and NASH cirrhosis (NCT02462967), using galectin-3 inhibitors.